CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. reporting person Jorey Chernett reported selling shares and ceased to beneficially own more than 5% of CVRx common stock on September 30, 2026. As of October 2, 2026, Chernett beneficially owned 165,000 shares, approximately 0.62% of the class, with sole voting and dispositive power over those shares. The percentage is based on 26,641,597 common shares outstanding as of July 30, 2026. Chernett's 165,000 shares were acquired in private transactions using $475,200 in personal funds.
CVRx, Inc. (CVRX) announced that its Board of Directors has appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry will join on October 12, 2026 and assume CFO responsibilities after the company files its Form 10-Q for the quarter ending September 30, 2026, with Oasheim remaining during a transition period.
Landry brings over two decades of financial leadership in medical devices, including CFO roles at Nyxoah SA and Vapotherm, and prior experience at Medtronic and Salient Surgical Technologies. His compensation includes a $500,000 base salary, a 50% target cash incentive, and initial equity awards representing 0.80% of common shares, granted under the Nasdaq inducement grant exemption.
CVRx, Inc. (CVRX) is the subject of a new Schedule 13D filed by private investor Jorey Chernett. He reports beneficial ownership of 1,461,750 shares of CVRx common stock, representing approximately 5.5% of the outstanding shares, based on 26,641,597 shares outstanding as of July 30, 2026. These shares were acquired in private transactions using personal funds totaling $7,995,772.
Chernett states he purchased the shares because he believed they were undervalued and an attractive investment. He indicates he may buy or sell additional shares, engage in hedging or derivative transactions, and actively communicate with CVRx management, the board, and other shareholders. On August 24, 2026, he delivered a letter to CVRx’s Board of Directors urging the Board to retain an independent financial advisor and initiate a review of strategic alternatives, with a sale of the company as the priority outcome.
CVRx, Inc. disclosed that investor Jorey Chernett beneficially owns 1,461,750 shares of its common stock, $0.01 par value. Based on 26,641,597 shares outstanding as of July 30, 2026, this position represents 5.5% of the company’s common stock.
Chernett reports sole voting and dispositive power over all 1,461,750 shares and no shared voting or dispositive authority.
CVRx, Inc. chief operating officer Brent Binkowski purchased 26,223 shares of common stock on August 13, 2026 in open-market or private transactions at a weighted average price of $2.9147 per share, with individual trade prices ranging from $2.87 to $2.96. Following these purchases, he directly holds 56,514 shares of CVRx common stock.
CVRx, Inc. chief operating officer Brent Binkowski reported a mandated sale of 1,309 shares of common stock on August 12, 2026. The shares were sold in a sell-to-cover transaction to satisfy tax withholding obligations at a weighted average price of $2.5502 per share, with individual prices between $2.55 and $2.564. Following this transaction, Binkowski directly holds 30,291 shares of CVRx common stock. The transaction is affirmed as made under a Rule 10b5-1 trading plan.
CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement. The company also announced a sales leadership transition in which Paul Verrastro, a long-time CVRx executive with more than 30 years of medical device sales and marketing experience, has been appointed Interim Head of Sales effective immediately while a search for a permanent successor is conducted. Management stated that a revised commercial outlook and the need to improve commercial execution led to the change in sales leadership.
CVRx, Inc. reported second quarter 2026 revenue of $15.7 million, up 16% from the prior-year quarter, driven mainly by U.S. heart failure sales. U.S. revenue was $14.8 million with 466 revenue units and 258 active implanting centers, while Europe revenue declined to $0.9 million on 40 units.
Gross profit rose to $13.7 million and gross margin improved to 87% from 84% a year earlier. Operating expenses were $26.7 million, resulting in a net loss of $14.0 million, or $0.53 per share, slightly better than the $14.7 million loss, or $0.57 per share, in 2025. Cash and cash equivalents totaled $64.6 million, and long-term debt was $58.6 million as of June 30, 2026.
Humana adopted a Medicare Advantage coverage policy for Barostim effective May 1, 2026, covering FDA-approved and BENEFIT-HF trial patients; management describes this as the third significant reimbursement development this year. For the third quarter of 2026, the company expects total revenue between $13.5 million and $14.5 million and notes headwinds from fewer sales territories, lower sales force productivity, and challenges with a large payer.
CVRx, Inc. announced that Chief Financial Officer Jared Oasheim has notified the company of his intention to resign to pursue other professional opportunities. He will remain CFO and principal accounting officer until a successor starts, then stay employed full-time at his current base salary until at least August 31, 2026 or 30 days after the transition.
Under an Employment Transition Agreement dated June 8, 2026, he will be available as a consultant through February 2027 at $245 per hour. He remains eligible for his full 2026 cash incentive payout based on the company’s actual results, will receive $262,000 in transition-related cash payments in two installments, and has the post-termination exercise period for certain pre-July 2021 stock options extended to three months after the consulting period. CVRx will also reimburse up to $10,000 of his legal fees for reviewing the agreement and has begun a search for the next CFO.